Outcome of Reverse Switching From CT-P13 to Originator Infliximab in Patients With Inflammatory Bowel Disease
SourceInflammatory Bowel Diseases, 27, 12, (2021), pp. 1954-1962
Article / Letter to editor
Display more detailsDisplay less details
Inflammatory Bowel Diseases
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.